Effects of Procainamide and Quinidine
SUMMARY Thirty-three patients with Wolff-Parkinson-White syndrome were studied electrophysiologically before and after administration of intravenous procainamide and oral quinidine sulfate. Procainamide prolonged the shortest R-R (SRR) interval between two consecutive pre-excited beats during atrial fibrillation 20-70 msec in 15 of 21 patients with no change observed in 6 of 21 patients.
Quinidine sulfate prolonged the SRR 20-170 msec in all 16. In 14 of 18 patients where procainamide and quinidine were comparable, quinidine prolonged the SRR 30-100 msec more than procainamide.
RECENT DEVELOPMENTS in methods of preoperative and operative technique have established the potential role of surgical intervention for treatment of selected cases of the pre-excitation syndrome refractory to medical management."s 2 The selection of optimal medical therapy has also been given a more rational basis by combining electrophysiologic studies with pharmacologic trials.3'1-The antegrade and retrograde effective refractory periods of normal and accessory pathways may have prognostic importance Procainamide and quinidine both tended to prolong the effective refractory period of atrial, ventricular, and accessory pathway tissue as well as to slow antegrade and retrograde conduction in the accessory pathway. However, exceptions were noted.
The assessment of pharmacological effects was frequently limited using determinations of refractory periods alone. Because of the variability observed in drug response, patients with Wolff-Parkinson-White syndrome and a history of atrial fibrillation with a rapid ventricular response should have atrial fibrillation electively induced while on therapy with procainamide or quinidine. when used to assess the potential value of various pharmacologic agents. However, these measurements cannot always be made because of atrial and ventricular muscle refractoriness. Additional information is provided by elective induction of atrial fibrillation before and after drug administration. Several authors have described an approximately linear relationship between the antegrade effective refractory period (AERP) of the accessory pathway (AP) and the maximal ventricular response during atrial fibrillation.' 121 The purpose of this study was to evaluate the usefulness of both refractory period determination and elective induction of atrial fibrillation in assessing the effect of antiarrhythmic therapy in patients with pre-excitation.
Materials and Methods
Thirty-three patients (25 male, 8 female) with Wolff-Parkinson-White syndrome were selected for drug study because the short ERP of their accessory pathway (AP) per-mitted a rapid ventricular response during atrial fibrillation. Their ages ranged from 13 to 59 years. All presented with recurrent tachyarrhythmias, some of which were lifethreatening. Most were referred as potential candidates for surgical division of the AP. All studies (except one) were performed in the postabsorptive nonsedated state after informed consent had been obtained. Antiarrhythmic therapy was discontinued at least 48 hours prior to the time of study.
Under local anesthesia using sterile technique, two quadripolar electrode catheters for recording and stimulating were percutaneously introduced via the right femoral vein and advanced under fluoroscopic control to the apex of the right ventricle (RV) and the right atrium (RA). A third quadripolar electrode catheter was introduced via an antecubital vein, generally the left, and advanced to the coronary sinus (CS). A tripolar electrode catheter was also percutaneously introduced via the right femoral vein and positioned across the tricuspid valve to record a His bundle electrogram (HBE).
Following introduction of all catheters, 100 units/kg of heparin was given intravenously. Standard ECG leads I and/or V, and electrograms from the RV, the low lateral RA, the His bundle and the proximal and distal CS were recorded simultaneously and stored on magnetic tape at 33/4 inches/sec. Graphic records were obtained simultaneously at the time of study or at a later date by playback from tape onto a Mingograph 800-8 channel ink-jet recorder at speeds of 100-200 mm/sec. A simultaneous 10 msec time code was recorded with the data. Intracardiac electrograms were recorded at filter frequencies of 50 to 1000 Hz. Stimulation studies were performed using a specially designed stimulator* which delivered impulses of 2 msec duration at twice diastolic threshold. All electrical equipment was carefully grounded.
The antegrade and retrograde refractory periods of the normal and accessory pathways were determined using the extrastimulus technique.'6 The methods used in the investigation of these patients have been described in detail elsewhere. 12, [17] [18] [19] [20] After control refractory periods were determined, atrial fibrillation was induced by pacing the RA or CS at cycle lengths of 150-200 msec if it did not occur spontaneously. Stimulation was begun using pulses of 2 msec duration delivered at twice diastolic threshold. If atrial fibrillation did not result, the pulse duration was gradually increased to 6 msec and the milliamperage of the stimulus gradually increased. When pacing the CS, preliminary pacing at a slow rate was always done first to be sure that the left ventricle was not actually being paced through the wall of the coronary sinus. Following the completion of these control studies, procainamide, 10-12 mg/kg, was given intravenously as a 50 mg bolus every 2 min. Twenty minutes were allowed for equilibration, following which antegrade and retrograde refractory periods were repeated, as was the induction of atrial fibrillation. A blood level was drawn. At the end of the initial study, all catheters were removed with the exception of the CS catheter. The latter was frequently left in place to facilitate control of reciprocating tachycardia (RT). In 23 of 33 patients studied, the patient was then returned to the ward and placed on oral quinidine sulfate, 200400 mg, every six hours for 2-4 days or until therapeutic blood levels were obtained. During this period, continuous telemetry to the coronary care unit was used to monitor cardiac rhythm. The patient was then completely restudied in the same manner as in the control state, approximately two hours after the last administered dose of quinidine sulfate.
Complications
Of the 33 patients studied, ten required cardioversion from atrial fibrillation induced during study. Two patients developed thrombophlebitis in the catheterized femoral vein, requiring ten day courses of intravenous heparin. One patient developed thrombocytopenic purpura on quinidine sulfate. All recovered uneventfully with treatment.
Drug Levels
Procainamide. Levels were determined by the spectrophotometric method.2" Therapeutic levels range from 2-8 mg/L (± 0.05 mg/L). Plasma levels were measured at the completion of the study, generally immediately after induction of atrial fibrillation, approximately one hour after drug infusion.
Quinidine. Levels were determined by the fluorometric method. The therapeutic range was 2-6 mg/L (± 0.05 mg/L).Y Levels were drawn two hours after oral dosage (beginning of study) and again at completion of study.
Definitions of Terms
The antegrade "echo interval" was defined as the interval during which a premature atrial impulse (A2) delivered during a basic cycle length (A,A,) resulted in an echo beat or sustained reciprocating tachycardia utilizing the accessory pathway. This was measured by subtracting the shortest ALA2 interval resulting in tachycardia from the longest A,A2 interval resulting in tachycardia. A similar retrograde echo interval was defined by corresponding ventricular stimulation data.
The ventricular response following induction of atrial fibrillation was analyzed by measuring the shortest R-R interval (SRR) between two successive pre-excited beats as well as the average R-R interval (ARR) of successive pre-excited beats over several minutes. Hereafter in this manuscript, these terms will describe intervals between consecutively pre-excited beats unless otherwise indicated.
Results
A total of 33 patients with the Wolff-Parkinson-White syndrome underwent study. Twenty-eight patients received procainamide and 23 patients received quinidine sulfate. Eighteen patients were studied on procainamide and quinidine on separate occasions. Table I lists the breakdown of the patients in the study. Table 2 lists the pertinent clinical data on the patients studied and the effects of procainamide and quinidine sulfate on the SRR interval and ARR interval between successive pre-excited beats during atrial flutter-fibrillation. Observations during atrial flutter-fibrillation before and after administration of procainamide could be made in 21/28 patients. Procainamide resulted in prolongation of the SRR 20-70 msec in 15/21, and resulted in no significant change (± 10 msec) in 6/21. Procainamide prolonged the ARR 15-135 msec in 13/21, decreased the ARR 15-35 msec in 4/21, and resulted in no significant change in 4/21. In the three patients excluded from analysis because only atrial flutter was induced, the SRR during atrial flutter was prolonged 5-60 msec.
Effect of Quinidine Sulfate on Atrial Flutter-Fibrillation
Observations in atrial flutter-fibrillation before and after administration of quinidine sulfate could be made in 16/23 patients. Quinidine prolonged the SRR 20-170 msec in 16/16 patients. Quinidine prolonged the ARR 15-170 msec in 12/16, decreased the ARR 54 msec in 1/16, and resulted in no significant change in 3/16.
Comparative Effect of Procainamide and Quinidine on Induced

Atrial Flutter-Fibrillation
Of the 18 patients who received both procainamide and quinidine, 14/18 had more prolongation of the minimum R-R interval (30-100 msec) on quinidine than on procainamide. Of these 14, two patients (TJ, JC) had atrial flutter while on procainamide and atrial fibrillation while on quinidine; however, the ventricular response during atrial fibrillation while on quinidine was slower than that with atrial flutter while on procainamide. In one of the 18 Table 3 lists the effects of quinidine and procainamide on the refractory periods of the atrium, ventricle and accessory pathways. In the majority of patients in whom the atrial and ventricular refractory periods were measured, procainamide and quinidine increased or had no significant effect (± 10 msec) on these refractory periods. The refractory period decreased in five cases with procainamide and two cases with quinidine. These results are consistent with the results previously recorded in the literature.9-1, 23, 24 It was possible to determine and compare antegrade and retrograde refractory periods of the accessory pathway at any cycle length in only 11/33 patients because in others the atrium and/or ventricle became refractory. The greatest comparable numbers were obtained at a basic cycle length of 400 msec (table 4) . Both procainamide and quinidine tended in most to increase the antegrade and retrograde refractory periods of the accessory pathway. However, in one case (AB), procainamide decreased the retrograde refractory period determined at cycle length 400 msec. In another patient (KD), quinidine decreased the retrograde refractory period determined at cycle length 400 msec. No patient was noted to have a decrease in the antegrade refractory period of the accessory pathway following administration of procainamide or quinidine. These results are consistent with those reported in the literature.9-" Abbreviations: PA = procainamide; Q = quinidine; AF = atrial fibrillation; BL = blood level; nl = normal; TDIV = total dose, intravenously; P Q46 = oral dose, every six hours; TD total dose; Fib = fibrillation; RT = reciprocating tachycardia; S = septal accessory atrioventricular pathway; R = right free-wall accessory atrioventricular pathway; Lleft free-wall accessory atrioventricular pathway; LGL = Lown-Ganong-Levine.
Effect of Procainamide and Quinidine on Antegrade and Retrograde Conduction
An attempt was made in 13 patients to assess the effect of procainamide and/or quinidine on the shortest cycle length of pacing which resulted in 1: 1 antegrade conduction over the accessory pathway. These observations are detailed in table 3.
Observations were made on ten patients before and after administration of procainamide. The minimum cycle length at which 1: 1 antegrade conduction occurred was increased in six (i.e., conduction slowed), decreased in one, and remained the same (+ 10 msec) in three. Observations were also made before and after administration of quinidine in ten patients. The minimum cycle length at which 1:1 conduction occurred was increased in six, decreased in three, and remained the same in one.
Assessment of the minimum cycle length associated with 1: 1 retrograde conduction over the accessory pathway was limited in many patients by precipitation of reciprocating tachycardia. In seven patients studied on procainamide, the minimum cycle length associated with 1: 1 retrograde conduction increased in four, decreased in two, and remained the same in one following the administration of procainamide. Five patients had data amenable to comparison before and after the administration of quinidine. In all five, quinidine increased the minimum cycle length associated with 1:1 retrograde conduction.
Effect of Procainamide and Quinidine on the Echo Interval
The effect of procainamide and quinidine on the echo interval in 12 patients where this could be assessed is shown in table 5. In three patients, quinidine widened the echo interval, i.e., reciprocating tachycardia was more easily induced by premature atrial beats and/or premature ventricular beats. In these cases the premature beats caused block in the accessory pathway, thus allowing dissociation of the 210  230  210  220  240  230 <220 <250 <245 <260 <265 <255  240  260  220  240  260 260  400  170  230  210  200  220  220 <205 <250  250 <235  260 <250  SF 5 600  235  240  250  230  230  255 <275 <260 <300 <280 <250 <280  210 normal and accessory pathway, resulting in re-entry. In two of these three patients, the echo interval was also widened on procainamide therapy. In the third patient (JD), procainamide decreased the ability to induce reciprocating tachycardia.
A representative example of one of the above phenomenon is shown in figure 1 . In panel A, the right atrium is being paced at a basic cycle length of 600 msec. A premature atrial depolarization introduced at a coupling interval of 320 msec conducts with pre-excitation and no RT results. Panel B shows the same patient during study with a quinidine blood level of 5.9 mg %. Again the right atrium is being paced at a basic cycle length of 600 msec. An atrial premature depolarization is again introduced at an identical coupling interval of 320 msec. This premature beat blocks in the accessory pathway and initiates an episode of RT with left bundle branch block aberration. In this patient, no episode of RT could be induced during the control refractory period determination made at a cycle length of 600 msec. Following administration of quinidine, RT was easily and reproducibly induced during a refractory period determination at the same cycle length. The atrial premature depolarizations which precipitated the arrhythmia had coupling intervals of 340-280 msec after the last drive cycle.
In two cases (SF, DL), RT was not observed during the control state or following the administration of procaina-mide due to the co-existence of atrial fibrillation. In each of these two cases, however, administration of quinidine converted atrial fibrillation or flutter into RT, which was then well sustained. In one patient (DDup), RT rapidly deteriorated into atrial fibrillation in the control state. Administration of procainamide stabilized this situation somewhat but deterioration of RT into atrial fibrillation was still observed. During therapy with quinidine, the RT was markedly stabilized and did not deteriorate into atrial fibrillation.
In four cases (DDot, JD, RR, DF), procainamide decreased the echo window and thus decreased the ability to induce RT. In three patients (FR, RR, DF), quinidine eliminated the echo window.
In the remaining patients, procainamide and quinidine had no significant effect on the echo window.
Discussion
Patients with the Wolff-Parkinson-White syndrome are susceptible to two types of dysrhythmia: reciprocating tachycardia and atrial flutter-fibrillation with a rapid ventricular response resulting from antegrade conduction over the accessory pathway. In some patients, these two dysrhythmias appear to stem from the same cause, as evidenced by the occasional observation of reciprocating tachycardia spontaneously deteriorating into atrial fibrillation. In other patients, the presence of an accessory pathway does not seem to be related to a condition of recurring atrial fibrillation. Ideally, therapeutic decisions should be based on a known mechanism of arrhythmia coupled with a thorough knowledge of a given pharmacological agent's effect on both the precipitating factors (i.e., ectopic beats, atrial fibrillation, etc.) and the mechanism responsible for sustaining the dysrhythmia (i.e., conduction and refractoriness of the atrium, ventricle, and the normal and accessory pathways linking these antegrade and retrograde).
In the case of reciprocating tachycardia, therapy may be aimed at reducing the number of premature beats, narrowing the echo interval (interval during which premature beats can dissociate the normal and accessory pathways) and prolonging refractoriness so that the returning impulse blocks 
Effect of quinidine on the echo interval for induction of reciprocating tachycardia. In the upper and lower panels tracings from above down are standard ECG lead V1 and bipolar electrograms from the right ventricular apex (R V), the right atrium (RA), the His bundle electrogram (HBE) and the proximal distal coronary sinus (CS). In the upper panel the right atrium is being paced at a cycle length of 600 msec. Following 8 basic drive beats, a premature atrial depolarization is introduced at a coupling interval of 320 msec and conducts with pre-excitation. In the lower panel this same sequence is performed in the presence ofa therapeutic blood level ofquinidine. A premature atrial depolarization at the same coupling interval now evokes a sustained episode of reciprocating tachycardia with LBBB aberration. either in the accessory pathway or the normal pathway. Which of these electrophysiological effects is responsible for the therapeutic action of quinidine or procainamide is still not known and the answer would require extensive ambulatory monitoring of the patient before and after therapy. Such studies are currently under way at our institution. We have observed some patients who are asymptomatic on medical therapy and who can have episodes of dysrhythmia during programmed stimulation of the atrium. In these patients, the predominant therapeutic effect seems to be due to suppression of the initiating event. The effect of procainamide or quinidine on the sustaining mechanism of reciprocating tachycardia depends largely upon their influence on the length of the circulatory wave (mean conduction velocity times the refractory period). To be effective, the drug must increase the length of the refractory period of the different components of the tachycardia circuit more than it decreases the mean conduction velocity of the circulating wave. 25, 26 This will differ from patient to patient thus making a priori prediction of the effectiveness of an antiarrhythmic agent impossible. The findings in three patients in this study in whom the drugs actually lengthened the echo interval confirm clinical observations that some patients became more symptomatic on therapy. The effects of procainamide and quinidine on reciprocating tachycardia depend on the underlying mechanisms of initiating and sustaining the arrhythmia in individual patients.
In the second large group of dysrhythmias associated with pre-excitation, that of atrial flutter-fibrillation associated with a rapid ventricular response over the accessory pathway, we can objectively assess in individual patients the potential for sustaining a rapid ventricular response during atrial fibrillation, and the ability of a pharmacological agent to modify this response. If the refractory period of the accessory pathway is short, for example, there is the risk of rapid conduction of atrial impulses over the accessory path resulting in a life-threatening ventricular response and ventricular fibrillation. This has been proposed as a possible cause of sudden death in patients with pre-excitation syndrome by Dreifus et al. 27 and Spurrell et al.28 However, as noted from our results and those of others,3 11 measurements of refractory periods of the A-V node and the accessory pathway are often limited by the refractoriness of atrial and ventricular muscle. The assessment of the effectiveness of a particular antiarrhythmic regimen, aside from the clinical course, has been previously based largely on modification of the degree of pre-excitation, and/or the ease of induction of reciprocating tachycardia. The effect of drug therapy on the most life-threatening aspect of the syndrome, that of a rapid ventricular response during atrial fibrillation, cannot be determined until the patient experiences a new episode of atrial fibrillation.
In our own experience, the first episode of atrial fibrillation in a patient's course is easily converted with no lasting clinical effects. While we are not suggesting, at this point, that patients with pre-excitation having properties of rapid conduction should receive prophylactic medication for this condition, we do recommend that an objective basis for pharmacological therapy in patients who have previously sustained a life-threatening ventricular response during atrial fibrillation be sought. This objective is easily obtained via elective induction of atrial fibrillation.
The elective induction of atrial fibrillation allows the separation of our patients into two groups: those with accessory pathways which allow life-threatening ventricular responses and those with less life-threatening ventricular arrhythmias. Clinical correlation between the spontaneous clinical events occurring outside the hospital and the laboratory values measured during atrial fibrillation has been excellent. We have noted in ongoing studies that the observation of very short R-R intervals (i.e. s 205 msec) during induced atrial fibrillation readily identifies those patients who have experienced life-threatening ventricular arrhythmias (ventricular fibrillation, cardiac arrest, and/or ventricular responses with cycle length of 200 msec) during spontaneous clinical events prior to their referral for evaluation. The effect of antiarrhythmic agents in this context may be evaluated by reinducing atrial fibrillation following drug administration and observing the R-R intervals. This method has been associated with low morbidity and no mortality.
It appears from our data that both procainamide and quinidine do effectively increase the cycle length of the shortest R-R interval during atrial fibrillation. This was consistent with the increase in antegrade refractory period of the accessory pathway noted in patients in whom the exact refractory period could be measured. The ability of these drugs to prolong the antegrade refractory period as noted in our study is in agreement with similar observations by other gr s 5 , 9,1, 1,1 1 groups.''
The potential for becoming more symptomatic on therapy was also demonstrated in this group of dysrhythmias. Procainamide and quinidine sufficiently slowed the atrial rate during atrial flutter-fibrillation in four cases such that 1:1 or 2:1 A-V conduction resulted with a more rapid ventricular response. In three additional cases, procainamide or quinidine stabilized a tendency to develop atrial fibrillation, allowing sustained reciprocating tachycardia to ensue.
Because of the variability observed from patient to patient, even at comparable drug levels, patients with the Wolff-Parkinson-White syndrome and a history of atrial fibrillation with a rapid ventricular response should have atrial fibrillation electively induced while on therapy with procainamide or quinidine.
